Wassmann, B <br/><br/>
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.  [electronic resource] 

 -  Bone marrow transplantation  Oct 2001 
 - 721-4 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Standard No.: </label>10.1038/sj.bmt.1703222  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Agents, Alkylating--therapeutic use<br/>Benzamides<br/>Bone Marrow Transplantation--adverse effects<br/>Colitis--chemically induced<br/>Combined Modality Therapy<br/>Enzyme Inhibitors--adverse effects<br/>Female<br/>Graft Survival<br/>Graft vs Host Disease--etiology<br/>Graft vs Leukemia Effect<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Hydroxyurea--therapeutic use<br/>Imatinib Mesylate<br/>Immunosuppression Therapy<br/>Interferon-alpha--therapeutic use<br/>Leukemia, Myeloid, Accelerated Phase--drug therapy<br/>Leukemia, Myeloid, Chronic-Phase--drug therapy<br/>Lymphocyte Transfusion<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm, Residual<br/>Neutropenia--chemically induced<br/>Piperazines--adverse effects<br/>Pyrimidines--adverse effects<br/>Remission Induction<br/>Salvage Therapy<br/>Transplantation Conditioning<br/>Transplantation, Homologous